Online inquiry

IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2183MR)

This product GTTS-WQ2183MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL15RA gene. The antibody can be applied in Bladder Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001243539.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3601
UniProt ID Q13261
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2183MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9375MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ2354MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ12710MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ4818MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ13132MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ5582MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7766
GTTS-WQ3513MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ491MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 47H4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW